Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma
NCT07243691
·
clinicaltrials.gov ↗
NA
Phase
RECRUITING
Status
33
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
DRUG:
Tislelizumab: 200mg, intravenous infusion, Q3W
Sponsor
Sir Run Run Shaw Hospital